NSCLC with LKB1 inactivation or disruption of the KEAP1-NRF2 pathway exhibits primary resistance to PD-1/PD-L1 blockade of PD-L1 expression and high TMB. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.